A Phase 1/2 interventional study of PET/MR Imaging and 64Cu-FBP8 in Alzheimer Disease and Dementia of Alzheimer Type, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Massachusetts General Hospital · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.
Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1/2, and was the 17th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 55+
Massachusetts General Hospital · Sites in United States
Ages 50–80 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 55–90 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–100 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 40–99 · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 20 across the 25 interventional studies, 129 across the 4 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
6 of the studies in Alzheimer Disease by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT06538311Massachusetts General HospitalTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease | 2027-03-31 |
| NCT05776641Massachusetts General HospitalGamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease | 2027-05 |
| NCT07236190Massachusetts General HospitalBiomarker-based Trial of NPC-1 for Alzheimer's Pathology | 2027-06 |
| NCT05904132Massachusetts General HospitalIndividual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
While there are many potential therapeutics being evaluated for Alzheimer's disease and related dementias (ADRD), there is currently no known cure for ADRD and its origin and pathophysiology are still not well understood. However, the association of fibrin with ADRD is becoming increasingly clearer. Up to now it was not possible to quantify brain fibrin in vivo to better elucidate its role in ADRD, but recently, 64Cu-FBP8 was proposed as a tool to detect thrombus anywhere in the body. This unique tool will allow us to non-invasively assess brain fibrin levels in at-risk and ADRD subjects.
The goal of this project is to use 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to assess fibrin levels. It is expected that about 30 people will take part in this research study. 64Cu-FBP8-PET is not currently approved by the U.S. Food and Drug Administration (FDA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cognitively Normal Subjects and ADRD subjects
Diagnostic Test: PET/MR Imaging · Drug: 64Cu-FBP8
PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
Also known as: Positron Emission Tomography/Magnetic Resonance Imaging
Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
Also known as: Positron Emission Tomography dye
Concentration of fibrin in the brains of ADRD subjects and healthy controls
64Cu-FBP8-PET will be used to quantify brain fibrin content in the brains of ADRD subjects and healthy controls to evaluate potential regional differences.
Time frame: baseline
Started Mar 2022 (actual). Primary completion is estimated for Sep 2026, 53 months after the start.
Of 35 non-industry phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 53 months is above that.
Counting every sponsor, half of 62 studies reached it within 45 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Copper Cu 64 FBP8
Massachusetts General Hospital →